A61K 31/42
Oxazoles
A61K31/42 (Oxazoles) appears on 3,196 US grants and 5,350 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,196
- Published applications
- 5,350
- Assignees
- 1,958
- Inventors
- 11,686
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 10 | 0 |
| 1977 | 4 | 0 |
| 1978 | 9 | 0 |
| 1979 | 7 | 0 |
| 1980 | 3 | 0 |
| 1981 | 4 | 0 |
| 1982 | 3 | 0 |
| 1983 | 4 | 0 |
| 1984 | 5 | 0 |
| 1985 | 11 | 0 |
| 1986 | 4 | 0 |
| 1987 | 5 | 0 |
| 1988 | 4 | 0 |
| 1989 | 8 | 0 |
| 1990 | 12 | 0 |
| 1991 | 7 | 0 |
| 1992 | 18 | 0 |
| 1993 | 20 | 0 |
| 1994 | 14 | 0 |
| 1995 | 17 | 0 |
| 1996 | 41 | 0 |
| 1997 | 47 | 0 |
| 1998 | 30 | 0 |
| 1999 | 38 | 0 |
| 2000 | 54 | 0 |
| 2001 | 55 | 21 |
| 2002 | 57 | 79 |
| 2003 | 60 | 175 |
| 2004 | 63 | 210 |
| 2005 | 56 | 186 |
| 2006 | 95 | 151 |
| 2007 | 48 | 129 |
| 2008 | 56 | 132 |
| 2009 | 41 | 141 |
| 2010 | 65 | 140 |
| 2011 | 58 | 163 |
| 2012 | 78 | 164 |
| 2013 | 102 | 206 |
| 2014 | 147 | 274 |
| 2015 | 165 | 263 |
| 2016 | 178 | 283 |
| 2017 | 227 | 312 |
| 2018 | 198 | 287 |
| 2019 | 183 | 255 |
| 2020 | 172 | 277 |
| 2021 | 144 | 269 |
| 2022 | 145 | 266 |
| 2023 | 125 | 231 |
| 2024 | 113 | 258 |
| 2025 | 109 | 252 |
| 2026 | 77 | 226 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Small molecule inhibitors of viral replication6 Oct 2026US 12,751,963 B2The Trustees of Princeton University
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Compositions for the treatment of rheumatoid arthritis and methods of using same29 Sep 2026US 12,747,487 B2Regeneron Pharmaceuticals, Inc.
- Method for preventing and/or treating liver fibrosis by using 6-methoxybenzoxazolinone and Coix lachryma-jobi L. extract comprising 6-methoxybenzoxazolinone15 Sep 2026US 12,734,157 B2Taichung District Agricultural Research and Extension Station, Ministry of Agriculture
- Methods of treating spinal cord injury or damage15 Sep 2026US 12,734,159 B2Spinogenix, Inc.
- Hyaluronic acid hydrogels with agent to enhance resorption8 Oct 2026US 2026/0306398 A1Boston Scientific Scimed, Inc.
- Trem2 agonists for the stimulation of microglia and methods of identification8 Oct 2026US 2026/0306439 A1The Translational Genomics Research Institute
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Combination therapy for pulmonary hypertension8 Oct 2026US 2026/0306461 A1Vivus, Inc.
- Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof8 Oct 2026US 2026/0306471 A1Insilico Medicine IP Limited
Most cited
By later US patents
- Methods and devices for providing prolonged drug therapy267US 6,919,373 B1Alza Corporation · 2005
- Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions198US 7,048,906 B2Cedars-Sinai Medical Center · 2006
- Inhibitors of IMPDH enzyme190US 5,807,876 AVertex Pharmaceuticals Incorporated · 1998
- Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof170US 7,074,801 B1Eisai Co., Ltd. · 2006
- Pharmaceutical composition containing acid addition salt of basic drug163US 6,255,502 B1Farmarc Nederland BV · 2001